At a glance
Read the record in context
Retatrutide's triple-receptor identity and investigational status remain central to the page. A 144-hour reference supplies a model scale; a 10 mg supplier listing supplies a package total. Neither source transforms the other into a labeled personal plan or a preparation instruction.[1]
What the research says
The cited phase 1b study investigated retatrutide, then identified as LY3437943, in adults with type 2 diabetes. Seventy-two participants received study treatment across active, placebo, and dulaglutide groups. The 12-week design used subcutaneous injections and examined multiple ascending exposure levels under controlled research conditions.[2]
Safety and tolerability were the primary outcomes. Investigators also measured pharmacokinetics, daily plasma glucose, HbA1c, and body weight. Retatrutide exposure was dose proportional, and the reported half-life was approximately six days, providing the research context for the library's extended timing input.[2][1]
The publication describes an early study, with 29 participants discontinuing before completion. Its metabolic findings and adverse-event observations belong to that design and population. The triple receptor identity refers to GIP, GLP-1, and glucagon activity; it does not make retatrutide interchangeable with dual- or single-receptor compounds.[2]
Cited amounts
The library records 10 mg as a supplier catalog package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][3]
Explore the Retatrutide dosing chartHalf-life and timing
Six days per halving yields a 30-day span for five halvings. The intervening points place 25% at day 12 and 6.25% at day 24. At day 30 the starting quantity is reduced to 3.125%, rather than to zero. This is deliberately arithmetic-only: it excludes accumulation from multiple entries and any absorption phase. The library's study-context estimate remains an estimate throughout, so the clean month-long axis cannot establish a personal washout interval or a retatrutide dosing schedule.[1][5]
Explore the Retatrutide half-life modelReconstitution
A 10 mg package divided across an assumed 2 mL would yield 5 mg/mL. Dividing an illustrative 0.5 mg by that concentration gives 0.1 mL. Neither amount is drawn from a clinical dosing sequence here. The example addresses a common confusion in retatrutide calculator searches: changing the assumed liquid volume changes the volume associated with a stated mass, while the package's original mass stays fixed. A formula cannot choose the liquid volume or certify a supplier's preparation instructions.[3]
Tracking it in PinPoint
From a reference to a record
Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]
The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.
Get PinPoint on the App StoreFrequently asked questions
- How much reconstitution solution for 10 mg retatrutide?
- There is no water-volume choice inferred from the library's research citation. As arithmetic only, 10 mg divided by an assumed 2 mL gives 5 mg/mL. That assumption demonstrates the formula; it is not a preparation instruction or a retatrutide dosing schedule.[1][2]
- What can a retatrutide dosing schedule calculator infer from the vial size?
- A vial total supports inventory and conversion math. It does not supply a studied sequence of clinical amounts or timing. The library's investigational research status remains unchanged when a calculator produces a precise-looking milliliter result.[1][5]
- Why does a retatrutide chart still show a fraction after 30 days?
- Thirty days contains five of the stored six-day intervals. Repeated halving gives one thirty-second, or 3.125%, of the hypothetical starting quantity. The model never reaches exact zero at that point, and the calculation does not measure a person's concentration.[1][5]
- Can a peptide tracker app record Retatrutide?
- PinPoint's compound library includes Retatrutide. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]
Sources
Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.
- PinPoint compound library, RetatrutideSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
- PubMed pharmacology reference 36354040Identity and research summary checked against this document on 5 October 2026. PubMed abstract, retrieved through NCBI EFetch.Retrieved 2026-10-05 · library-reference
- Supplier catalog package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · supplier
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
- Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic